SARS-CoV-2 Diagnostic Testing
COVID-19
Key Facts
About Retrogen
Retrogen is an established, privately-held service provider in the genomics and diagnostics sector, leveraging both foundational Sanger sequencing and modern NGS platforms like Ion Torrent PGM and Oxford Nanopore. Its business model is dual-focused, serving research clients with genomic services while also operating a CLIA/CAP-accredited clinical lab for diagnostic testing, including COVID-19 and genetic disease panels. The company has built a stable revenue-generating operation by catering to diverse customer segments from academia to healthcare, though it operates in a highly competitive commoditized service market. Its strategic positioning combines technical reliability with a expansion into higher-value clinical diagnostic applications.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |